2023-11-09T15:41:19-06:00 2022-12-31 912011386 JACOBSON JARVIS & CO PLLC 200 1ST AVE W SUITE 200 SEATTLE WA 98119 990 2022-01-01 842240648 CURESHANK CURE 3104098060 433 N CAMDEN DRIVE 1100 BEVERLY HILLS CA 90210 ABBY LIEVENSE TREASURER 3104098060 2023-11-01 1 ABBY LIEVENSE 999009999 0 HOWARD DONKIN P00147726 2066288990 2023-11-01 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z GERALDINE BLISS 433 N CAMDEN DRIVE 1100 BEVERLY HILLS CA 90210 487302 0 X WWW.CURESHANK.ORG X 2019 CA TO ACCELERATE THE DEVELOPMENT OF TREATMENTS FOR PHELAN-MCDERMID SYNDROME AND SHANK-RELATED DISORDERS. 4 4 0 4 0 0 547552 487299 0 0 0 3 0 0 547552 487302 500 5000 0 0 0 0 0 0 0 17674 214660 18174 219660 529378 267642 586406 854048 0 0 586406 854048 X TO ACCELERATE THE DEVELOPMENT OF TREATMENTS FOR PHELAN-MCDERMID SYNDROME AND SHANK-RELATED DISORDERS. OUR APPROACH IS TO IDENTIFY AND FUND PROJECTS THAT OVERCOME CRITICAL BARRIERS TO SUCCESSFUL DRUG DEVELOPMENT AND TO COORDINATE SCIENTIFIC EFFORTS TO IMPROVE EFFICIENCY AND SPEED IN THE FIELD. 1 0 107292 5000 CURESHANK WILL BRING THE SCIENTIFIC COMMUNITY TOGETHER BY ORGANIZING SCIENTIFIC SYMPOSIA AND OTHER MEETINGS. WITH OUR SCIENTIFIC STAKEHOLDERS, WE WILL DEVELOP A RESEARCH ROADMAP TO A CURE FOR SHANK-RELATED DISORDERS. WE WILL ALSO SERVE AS AN HONEST BROKER TO ENABLE COLLABORATION AMONG SHANK RESEARCHERS AND COORDINATION OF THEIR PROJECTS TO IMPROVE THE SPEED AND EFFICIENCY OF RESEARCH. 85883 CURESHANK WILL FUND TARGETED RESEARCH STUDIES, INCLUDING SCIENTIFIC PROJECTS THAT ELUCIDATE THE UNDERLYING DISEASE MECHANISMS, THAT IDENTIFY AND VALIDATE TARGETS FOR DRUG DEVELOPMENT, AND THAT DE-RISK PROMISING DRUG TARGETS. CURESHANK WILL ALSO FUND CERTAIN PROMISING CLINICAL TRIALS READINESS INITIATIVES. THESE ACTIVITIES ARE NEEDED TO INCREASE THE NUMBER OF DRUG TARGETS MOVING FROM ACADEMIC RESEARCH LABS INTO SUCCESSFUL INDUSTRY-SPONSORED CLINICAL TRIALS. 900 CURESHANK WILL ADVOCATE FOR INCREASED FUNDING OF SHANK RESEARCH BY OTHER STAKEHOLDERS AND STRATEGIZE WITH RESEARCHERS ON INITIATIVES, SUCH AS SEED GRANTS, THAT COULD HELP ATTRACT RESEARCH INVESTMENT BY OTHER FUNDERS. 194075 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 4 4 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 0 0 0 0 CA X ABBY LIEVENSE 3104098060 433 N CAMDEN DRIVE 1100 BEVERLY HILLS CA 90210 X GERALDINE BLISS PRESIDENT 40.00 X X 0 0 0 PAULINA RYCHENKOVA SECRETARY 25.00 X X 0 0 0 ABBY LIEVENSE TREASURER 15.00 X X 0 0 0 TALYA EMERY SILVA VICE PRESIDENT 5.00 X X 0 0 0 0 0 0 0 0 0 0 0 487299 487299 3 3 487302 0 0 3 5000 5000 147808 147808 30067 30067 680 680 16919 16919 544 544 2644 2644 3507 3507 1291 1291 CONCEPTUAL MODEL 3700 3700 FAMILY STORIES 3600 3600 VOICE OF PATIENT REPORT 3000 3000 MEMBERSHIP FEES 900 900 219660 194075 25585 0 437681 853047 148725 1001 586406 854048 0 0 X 586406 854048 586406 854048 586406 854048 267642 0 X 0 0 0 X 24550 40500 547552 487298 1099900 24550 40500 547552 487298 1099900 178910 920990 3 3 5565 5565 1105468 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 FORM 990, PART III, LINE 2 THE CURESHANK BIOMARKERS AND OUTCOME MEASURES CONSORTIUM FACILITATES A COOPERATIVE, GLOBALLY ALIGNED EFFORT FOCUSED ON THE IDENTIFICATION AND DEVELOPMENT OF NOVEL APPROACHES TO ENABLE SUCCESSFUL CLINICAL TRIALS FOR PHELAN-MCDERMID SYNDROME. THE CONSORTIUM ESTABLISHES A PRE-COMPETITIVE SPACE FOR COMPANIES TO ADVANCE BIOMARKER RESEARCH EFFORTS AND OUTCOME MEASURES IN PHELAN-MCDERMID SYNDROME. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF FORM 990 IS PROVIDED TO THE GOVERNING BODY VIA EMAIL BEFORE IT IS FILED. FORM 990, PART VI, SECTION C, LINE 19 UPON REQUEST.